Novartis AG Global Capability Center (Hyderabad)

Novartis's India AI & Data Centre in Hyderabad is one of the most scientifically ambitious GCCs in India, operating as the India hub for Novartis's landmark Data42 programme — a company-wide initiative to leverage data science and AI to fundamentally accelerate drug discovery and development. Located in Genome Valley, Hyderabad's life sciences district, the centre employs over 3,000 data scientists, AI engineers, and computational biologists who are working on some of the most challenging problems in pharmaceutical AI: predicting molecular properties, identifying clinical trial patient populations, and mining real-world evidence to generate regulatory-grade insights.

The technology capabilities at Novartis India are genuinely at the frontier of pharmaceutical AI. Teams are deploying generative AI models for molecular design — using large language model architectures adapted for chemical structures to propose novel drug candidate molecules with desired properties. The clinical analytics team builds machine learning models that process electronic health record data, genomics datasets, and clinical trial endpoints to identify biomarkers and patient segments that respond to specific therapies. An AI Centre of Excellence coordinates these efforts and maintains connections with global Novartis data science teams in Basel and Cambridge.

Novartis India targets 4,000 employees by 2027, with growth concentrated almost entirely in AI, data science, and computational biology. Hyderabad's Genome Valley cluster, home to organisations including Dr. Reddy's Laboratories, Bharat Biotech, and CSIR-CCMB, provides a unique ecosystem that combines pharmaceutical industry expertise with computational talent. Novartis's investment in this location reflects a bet that the next generation of pharmaceutical innovation will be driven as much by data and AI as by traditional chemistry and biology — a bet that the India centre is actively helping to realise.

Parent Enterprise Overview